
Sadamoto Zenda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2596412/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Research policy in supportive care and palliative care for cancer dyspnea. Japanese Journal of Clinical Oncology, 2022, 52, 260-265.	1.3	7
2	Factors affecting the implementation of guideline-based prophylactic antiemetic therapy for chemotherapy-induced nausea and vomiting in Japan: a protocol for a hospital-based qualitative study. BMJ Open, 2022, 12, e055473.	1.9	2
3	Protocol for a multicentre, prospective, cohort study to investigate patient satisfaction and quality of life after immediate breast reconstruction in Japan: the SAQLA study. BMJ Open, 2021, 11, e042099.	1.9	5
4	Establishment of a research policy for supportive and palliative care in Japan. Japanese Journal of Clinical Oncology, 2021, 51, 538-543.	1.3	6
5	Phase 3 Randomized Trial of Topical Steroid Versus Placebo for Prevention of Radiation Dermatitis in Patients With Head and Neck Cancer Receiving Chemoradiation. International Journal of Radiation Oncology Biology Physics, 2021, 111, 794-803.	0.8	11
6	Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 242-249.	10.7	117
7	Hydrocolloid dressing as a prophylactic use for hand–foot skin reaction induced by multitargeted kinase inhibitors: protocol of a phase 3 randomised self-controlled study. BMJ Open, 2020, 10, e038276.	1.9	3
8	Quality Assessment in Supportive Care in Head and Neck Cancer. Frontiers in Oncology, 2019, 9, 926.	2.8	8
9	A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study). Frontiers in Oncology, 2019, 9, 6.	2.8	9
10	Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer. International Journal of Clinical Oncology, 2019, 24, 789-797.	2.2	12
11	The post hoc analysis comparing the severity grades of chemoradiotherapy-induced oral mucositis scored between the central and local assessors in a multicenter, randomized controlled trial of rebamipide for head and neck cancer. International Journal of Clinical Oncology, 2019, 24, 241-247.	2.2	6
12	Topical steroid versus placebo for the prevention of radiation dermatitis in head and neck cancer patients receiving chemoradiotherapy: the study protocol of J-SUPPORT 1602 (TOPICS study), a randomized double-blinded phase 3 trial. BMC Cancer, 2018, 18, 873.	2.6	13
13	Fan Therapy Is Effective in Relieving Dyspnea in Patients With Terminally Ill Cancer: A Parallel-Arm, Randomized Controlled Trial. Journal of Pain and Symptom Management, 2018, 56, 493-500.	1.2	40
14	Overview of clinical research to establish EBM on Supportive/Palliative care in Japan. Japanese Journal of Head and Neck Cancer, 2018, 44, 276-279.	0.1	0
15	Proton beam therapy for olfactory neuroblastoma. Radiotherapy and Oncology, 2017, 122, 368-372.	0.6	33
16	Phase II study of proton beam therapy as a nonsurgical approach for mucosal melanoma of the nasal cavity or para-nasal sinuses. Radiotherapy and Oncology, 2016, 118, 267-271.	0.6	36
17	Multicenter Phase 2 Study of Cisplatin and 5-Fluorouracil With Concurrent Radiation Therapy as an Organ Preservation Approach in Patients With Squamous Cell Carcinoma of the Cervical Esophagus. International Journal of Radiation Oncology Biology Physics, 2016, 96, 976-984.	0.8	45
18	A prospective picture collection study for a grading atlas of radiation dermatitis for clinical trials in head-and-neck cancer patients, Journal of Radiation Research, 2016, 57, 301-306.	1.6	16

SADAMOTO ZENDA

#	Article	IF	CITATIONS
19	Multicenter phase II study of an oral care program for patients with head and neck cancer receiving chemoradiotherapy. Supportive Care in Cancer, 2016, 24, 3029-36.	2.2	27
20	DeCoP, a Dermatitis Control Program using a moderately absorbent surgical pad for head and neck cancer patients receiving radiotherapy: a retrospective analysis. Japanese Journal of Clinical Oncology, 2015, 45, 433-438.	1.3	10
21	Late toxicity of proton beam therapy for patients with the nasal cavity, para-nasal sinuses, or involving the skull base malignancy: importance of long-term follow-up. International Journal of Clinical Oncology, 2015, 20, 447-454.	2.2	22
22	Strontium-89 (Sr-89) chloride in the treatment of various cancer patients with multiple bone metastases. International Journal of Clinical Oncology, 2014, 19, 739-743.	2.2	27
23	Gastrostomy Dependence in Head and Neck Carcinoma Patient Receiving Post-operative Therapy. Japanese Journal of Clinical Oncology, 2014, 44, 1058-1062.	1.3	5
24	A Dermatitis Control Program (DeCoP) for head and neck cancer patients receiving radiotherapy: a prospective phase II study. International Journal of Clinical Oncology, 2013, 18, 350-355.	2.2	22
25	Phase II Study of Cetuximab Plus Concomitant Boost Radiotherapy in Japanese Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Japanese Journal of Clinical Oncology, 2013, 43, 476-482.	1.3	61
26	Impact of early radiological response evaluation on radiotherapeutic outcomes in the patients with nasal cavity and paranasal sinus malignancies. Journal of Radiation Research, 2012, 53, 704-709.	1.6	4
27	Induction Chemotherapy with Docetaxel, Cisplatin and S-1 Followed by Proton Beam Therapy Concurrent with Cisplatin in Patients with T4b Nasal and Sinonasal Malignancies. Japanese Journal of Clinical Oncology, 2012, 42, 691-696.	1.3	22
28	Non-surgical approach to small cell carcinoma of the esophagus: does this rare disease have the same tumor behavior as SCLC?. International Journal of Clinical Oncology, 2012, 17, 610-615.	2.2	22
29	Multicenter phase II study of an opioid-based pain control program for head and neck cancer patients receiving chemoradiotherapy. Radiotherapy and Oncology, 2011, 101, 410-414.	0.6	45
30	Proton Beam Therapy for Unresectable Malignancies of the Nasal Cavity and Paranasal Sinuses. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1473-1478.	0.8	79
31	Proton Beam Therapy as a Nonsurgical Approach to Mucosal Melanoma of the Head and Neck: A Pilot Study. International Journal of Radiation Oncology Biology Physics, 2011, 81, 135-139.	0.8	59
32	OPTIMAL TIMING OF ENDOSCOPIC EVALUATION OF THE PRIMARY SITE OF ESOPHAGEAL CANCER AFTER CHEMORADIOTHERAPY OR RADIOTHERAPY: A RETROSPECTIVE ANALYSIS. Digestive Endoscopy, 2009, 21, 245-251.	2.3	14
33	Feasibility Study of Single Agent Cisplatin and Concurrent Radiotherapy in Japanese Patients with Squamous Cell Carcinoma of the Head and Neck: Preliminary Results. Japanese Journal of Clinical Oncology, 2007, 37, 725-729.	1.3	54
34	Single-agent Docetaxel in Patients with Platinum-refractory Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN). Japanese Journal of Clinical Oncology, 2007, 37, 477-481.	1.3	29
35	<scp>Jâ€SUPPORT</scp> research policy for oral mucositis associated with cancer treatment. Cancer Medicine, 0, , .	2.8	2